Document is current

Article History

Received: 13 November 2020

Revised: 10 January 2021

Accepted: 15 January 2021

First Online: 19 February 2021

Compliance with ethical standards

:

: Dr. E. Ziv: Research grants from SIR, RSNA, NANETS, Cycle for survival, MSK Society, MSK FGI, AACR, Ethicon, and Novartis. All conflicts of interest are outside the submitted work. Dr. C.T. Sofocleous: Research Support from National Institute of Health (NIH, R01 CA240569-01). Research support from industry: SIRTEX Medical Inc, BTG and Ethicon J&J. Dr. Sofocleous is consultant/ member of advisory board for: J&J/ Ethicon, Terumo, BTG/Boston Scientific, SIRTEX, Varian. All conflicts of interest are outside the submitted work. Dr. F.E. Boas is a co-founder of Claripacs, LLC. He received research funding (investigator-initiated) from Guerbet. He received research support (investigator-initiated) from GE. He received research supplies (investigator-initiated) from Bayer. He received a research grant and speaker fees from Society of Interventional Oncology, which were sponsored by Guerbet. He attended research meetings sponsored by Guerbet. He is an investor in Labdoor, Qventus, CloudMedx, Notable Labs, and Xgenomes. He is the inventor and assignee on US patent 8233586, and is an inventor on US provisional patent applications 62/754,139 and 62/817,116. All conflicts of interest are outside the submitted work. Other authors have co conflicts of interest.

: IRB approval was obtained for this retrospective cohort study.

: All authors provided their consent for publication.

: For this type of study formal patient informed consent and consent for publication are not required.